API | sarizotan

sarizotan Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Sarizotan (EMD-128,130) is a selective 5-HT1A receptor agonist and D2 receptor antagonist, which has antipsychotic effects, and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa. ^Wikipedia

Chemistry

SMILES: Fc1ccc(-c2cncc(CNC[C@H]3CCc4ccccc4O3)c2)cc1
InChIKey: HKFMQJUJWSFOLY-OAQYLSRUSA-N
Mol. Mass: 348.42
ALogP: 4.37 Partition coefficient
ChEMBL Molecules:

sarizotan

sarizotan hydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
- D(3) dopamine receptor (Homo sapiens) ^UniProt
- D(4) dopamine receptor (Homo sapiens) ^UniProt
- 5-hydroxytryptamine receptor 1A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

emd128130 | emd 128130 | emd-128130 | sarizotan | sarizotan hcl | sarizotan hydrochloride

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Dyskinesias (Phase 3)

Parkinson Disease (Phase 3)

Rett Syndrome (Phase 2/Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue